Prostate Cancer Radiotherapy And Incidental Testicular Irradiation: Impact On Gonadal Function

Jul 20, 2023

The long-term impact of androgen suppression has largely been demonstrated in prostate cancer (PCa) patients, with a wide range of hormone-induced side effects, including an increased risk of cardiac events, osteoporosis, metabolic syndrome, and impaired sexual function [1,2]. While incidental testicular irradiation in PCa patients has long been known to impact Leydig cell function and testosterone production [3,4], the extent and clinical impact of testosterone decrease after exclusive radiotherapy remains largely undervalued. 

cistanche tubulosa powder

Click to cistanche beneficios for testosterone

Hereby, we aim to shed light on the existing evidence on incidental testicular irradiation and radiation-induced hypogonadism during PCa radiotherapy and discuss future technical developments to minimize testis irradiation. The existence of a dose–response relationship between the incidental testicular irradiation and the decrease of testosterone levels following curative external beam radiotherapy (EBRT) for PCa is far to be well established (Table 1). 


In patients treated to 68 Gy with standard fractionation using a 3-dimensional conformal radiotherapy (3D-CRT) technique and receiving a mean dose of 2 Gy to the testis, Zagars et al. estimated a 9% decrease rate in testosterone levels 3 months after irradiation but failed to demonstrate a clear correlation between testicular doses and a potential hypogonadal effect [5].


On the other hand, a linear relationship between the dose delivered to the testes and the risk to develop radiation-induced hypogonadism has been observed by Ishiyama et al. [6]: delivering a dose of 76 Gy with an intensity-modulated radiotherapy (IMRT) technique, the mean dose delivered to the testes increased proportionally to 5.3 Gy. A dose of 7 Gy delivered to the testis resulted in a 2-fold reduction in testosterone levels. 


After exclusive EBRT [7], 75% of the patients experienced a significant decrease in testosterone level, with a median decrease from baseline to the nadir of 30% and a median time to the first decrease of 6.4 months. Up to 45% of the patients experienced biochemical hypogonadism following curative EBRT, with a lower chance of testosterone recovery observed especially in patients with high body mass index, advanced age, and lower testosterone nadir. 

organic cistanche

While in most patients a complete recovery of testosterone levels is observed 12 to 18 months after the EBRT completion [8,9], up to 40% of the patients are unable to recover their baseline testosterone levels [9]. Although the impact of incidental testicular irradiation on gonadal function is determined, the further repercussion on sexual function remains to date speculative. 


As demonstrated by Yuan et al., despite the testosterone levels 19 months after SBRT returned to baseline and EPIC hormonal scores remained stable, patients showed a 10.9 point decline in the EPIC sexual scores at the 19- to 24-month time period, suggesting a more complex etiology of sexual dysfunction in patients treated with curative radiotherapy [10]. 


Although this decline in EPIC sexual domain scores was only consistent with a small-sized clinically detectable difference, attention to minimize the incidental testicular irradiation, together with dose optimization to organs at risks like the penile bulb, the pudendal arteries, or the neurovascular bundles [11–14] should be proposed in an attempt to preserve the erectile function. The relationship between the incidental testicular dose and the recovery time of testosterone to normal levels has been studied by Pickles et al. [15]. 


Higher doses delivered to the testicles are usually associated with a deeper and more prolonged testosterone nadir and a longer testosterone recovery time. Whether a prolonged testosterone recovery induced by testicular irradiation is associated with better biochemical disease control in the long term remains an unanswered and purely speculative question [16]. 

cistanche tubulosa dosage

Of note, time to testosterone recovery after high-dose radiotherapy combined with androgen deprivation has not been shown to impact clinical failure in the DART01/05 phase III randomized trial [17]. As far as the radiotherapy techniques are concerned, some points merit special consideration. First, while the widespread use of stereotactic body radiation therapy (SBRT) has the potential to decrease the integral dose to the testis compared to standard fractionated regimens, caution to avoid beams directly traversing the testicles and to limit the scattered dose is required when non-coplanar robotic arm devices are used [18]. 


In a series of 26 patients treated to 36.25 Gy in 5 fractions with a CyberKnife [19], the mean dose delivered to the testis was 2.1 Gy, similar to other series using 3D-CRT [20,21] or IMRT [6] techniques, but proportionally higher compared to schedules with higher total delivered doses. Nevertheless, in this series, with a median absolute decrease of 3.3 nmol/L at 1 year (–23%), no patient experienced treatment-related hypogonadism after treatment. In the largest series of 636 patients treated with SBRT, Yuan et al. were unable to demonstrate a significant change in testosterone levels, even if the subgroup of patients with normal pretreatment gonadal function was the only one to experience a significant decrease in the testosterone levels at all periods (approximately 20%) [10]. 


Second, routine use of image guidance using kilovoltage cone-beam computed tomography (kVCBCT) represents an additional source of incidental irradiation, resulting in up to a 300% increase in testicular dose [22]. While the dosimetric impact of online tumor tracking on the cumulative dose delivered to the testicles has to date not been investigated, non-ionizing tracking systems may represent a nonirradiating alternative for intra-fractional motion control [23].

cistanche tubulosa extract

Similarly, the use of adaptive systems using magnetic resonance-guided radiation therapy (MRgRT) may represent a further step forward in reducing radiation-induced toxicities as demonstrated by the MIRAGE phase III trial [24]. In summary, in the wide spectrum of radiation-induced toxicities, hypogonadism induced by incidental testicular irradiation constitutes an often neglected and underestimated side effect observed in men with PCa treated with curative radiotherapy. Although the relationship between sexual function and disease control remains to be elucidated, approaches in planning optimization and image guidance trying to limit testes doses are therefore highly encouraged when irradiating curatively PCa patients.

cistanche tubulosa capsules

References 

[1] D’Amico AV, Denham JW, Crook J, Chen M-H, Goldhaber SZ, Lamb DS, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol Off J Am Soc Clin Oncol 2007;25(17):2420–5. 

[2] Bruchovsky N, Klotz L, Crook J, Phillips N, Abersbach J, Goldenberg SL. Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer 2008;6(1):46–52. 

[3] Rowley MJ, Leach DR, Warner GA, Heller CG. Effect of graded doses of ionizing radiation on the human testis. Radiat Res 1974;59:665–78. 

[4] Izard MA. Leydig cell function and radiation: a review of the literature. Radiother Oncol J Eur Soc Ther Radiol Oncol 1995;34(1):1–8. 

[5] Zagars GK, Pollack A. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;39(1):85–9. 

[6] Ishiyama H, Teh BS, Paulino AC, Yogeswaren S, Mai W-Y, Xu Bo, et al. Serum testosterone level after intensity-modulated radiotherapy in low-risk prostate cancer patients: does testicular dose correlate with testosterone level? J Radiat Oncol 2012;1(2):173–7. 

[7] Pompe RS, Karakiewicz PI, Zaffuto E, Smith A, Bandini M, Marchioni M, et al. External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer. J Sex Med 2017;14:876–82. 

[8] Markovina S, Weschenfelder DC, Gay H, McCandless A, Carey B, DeWees T, et al. Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer. Pract Radiat Oncol 2014;4(6):430–6. 

[9] Pickles T, Agranovich A, Berthelet E, Duncan GG, Keyes M, Kwan W, et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 2002;94(2):362–7. 

[10] Yuan Ye, Aghdam N, King CR, Fuller DB, Weng J, Chu F-I, et al. Testosterone levels and sexual quality of life after stereotactic body radiation therapy for prostate cancer: a multi-institutional analysis of prospective trials. Int J Radiat Oncol Biol Phys 2019;105(1):149–54. 

[11] Roach M, Nam J, Gagliardi G, El Naqa I, Deasy JO, Marks LB. Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys 2010;76:S130-134. 

[12] Spratt DE, Lee JY, Dess RT, Narayana V, Evans C, Liss A, et al. Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial. Eur Urol 2017;72(4):617–24. 

[13] Teunissen FR. Neurovascular-Sparing MR-Guided Adaptive Radiotherapy in Prostate Cancer; Defining the Potential Population for Erectile Function-Sparing Treatment. J Sex Med n.d.:5. 

[14] Teunissen FR, Wortel RC, Hes J, Willigenburg T, de Groot-van Breugel EN, de Boer JCJ, et al. Adaptive magnetic resonance-guided neurovascular-sparing radiotherapy for the preservation of erectile function in prostate cancer patients. Phys Imaging Radiat Oncol 2021;20:5–10. 

[15] Pickles Tom, Graham Peter. Members of the British Columbia Cancer Agency Prostate Cohort Outcomes Initiative. What happens to testosterone after prostate radiation monotherapy and does it matter? J Urol 2002;167(6):2448–52. 

[16] King CR, Kapp DS. To treat pelvic nodes or not: could the greater testicular scatter dose from whole pelvic fields confound results of prostate cancer trials? J Clin Oncol 2009;27(36):6076–8. 

[17] Zapatero A, Alvarez ´ A, Guerrero A, Maldonado X, Gonz´ alez San Segundo C, Cabeza MA, et al. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial. Radiother Oncol 2021;160:115–9. 

[18] King CR, Lo A, Kapp DS. Testicular dose from prostate cyberknife: a cautionary note. Int J Radiat Oncol Biol Phys 2009;73(2):636–7. 

[19] Oermann EK, Suy S, Hanscom HN, Kim JS, Lei S, Yu X, et al. Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. J Hematol OncolJ Hematol Oncol 2011;4(1). 

[20] Grigsby PW, Perez CA. The effects of external beam radiotherapy on endocrine function in patients with carcinoma of the prostate. J Urol 1986;135:726–7.https://doi.org/10.1016/s0022-5347(17)45831-9. 

[21] Tomi´c R, Bergman B, Bamber J-E, Littbranb B, Lofroth ¨ PO. Effects of external radiation therapy for cancer of the prostate on the serum concentrations of testosterone, follicle-stimulating hormone, luteinizing hormone, and prolactin. J Urol 1983;130(2):287–9. 

[22] Deng J, Chen Z, Yu JB, Roberts KB, Peschel RE, Nath R. Testicular doses in image-guided radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 2012;82(1): e39–47. 

[23] Bell LJ, Eade T, Kneebone A, Hruby G, Alfieri F, Bromley R, et al. Initial experience with intra-fraction motion monitoring using Calypso-guided volumetric modulated arc therapy for definitive prostate cancer treatment. J Med Radiat Sci 2017;64: 25–34. 

[24] Kishan AU, Ma TM, Lamb JM, Casado M, Wilhalme H, Low DA, et al. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncol 2023.


You Might Also Like